Growth hormone secretagogues, often shortened to GH secretagogues or GHS, are compounds that stimulate the body's own growth hormone signaling rather than supplying recombinant human growth hormone directly. That difference is the center of the entire category.
The online version of the conversation is usually too simple. GH secretagogues are often marketed as "recovery," "anti-aging," "fat loss," or "sleep" peptides. Those claims compress a complex endocrine system into a slogan. The better question is: which compound, which receptor, which evidence level, which patient, and which monitoring plan?
Some GH secretagogues have human pharmacology data. Tesamorelin has FDA-approved use and Phase 3 clinical evidence in a specific HIV-associated lipodystrophy population. Others, such as ipamorelin, have a stronger mechanistic rationale than long-term adult outcome data. MK-677, also called ibutamoren, is a non-peptide oral GHS with human GH/IGF-1 data, but it is not the same thing as a prescribed peptide protocol.
This overview explains the category without treating every compound as equally proven.
Bottom line: GH secretagogues are an endocrine signaling category, not a single product — and evidence quality varies sharply by compound.
YourHealthRx framing: clinician-led signal literacy with baseline screening, IGF-1 monitoring, and regulatory review — not anti-aging or body-transformation marketing.
Quick Takeaways
- GH secretagogues stimulate endogenous GH release through upstream signaling, instead of replacing GH directly.
- Two major buckets matter: GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, and ghrelin/GHS-R agonists such as ipamorelin and MK-677.
- Evidence quality varies sharply by compound: tesamorelin has Phase 3 RCT evidence in HIV-associated lipodystrophy, while CJC-1295 and MK-677 have human GH/IGF-1 pharmacology data, and ipamorelin's best-known selectivity data are preclinical (PubMed CJC-1295, PubMed tesamorelin, PubMed MK-677, PubMed ipamorelin).
- Monitoring matters: IGF-1, glucose markers, edema, joint symptoms, cancer history, and contraindications are central to responsible use.
- Athletes need extra caution: WADA's 2026 Prohibited List includes GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, as well as GHS mimetics such as ibutamoren and ipamorelin (WADA 2026 Prohibited List).
- Legal and pharmacy status is not uniform: tesamorelin has an FDA-approved branded product for a specific indication, while many other compounds occupy evolving compounding and investigational-use territory.
How GH Secretagogues Work
Growth hormone is released by the anterior pituitary in pulses. Those pulses are regulated by hypothalamic signals, sleep, nutrition, exercise, age, sex hormones, glucose status, and negative feedback from IGF-1.
GH secretagogues work upstream of the pituitary. They try to increase the signal that tells the pituitary to release growth hormone. That is different from recombinant human growth hormone, which adds GH from the outside and can bypass normal pulsatile regulation.
The theoretical appeal is that secretagogues may preserve more physiological GH pulsatility and feedback. A review in Sex Medicine Reviews described GHS compounds as promoting pulsatile GH release subject to negative feedback, while also emphasizing that few long-term, rigorously controlled studies have examined their safety and efficacy (PMC review).
That is the honest frame: the mechanism is biologically coherent, but long-term outcomes are not equally proven across the class.
The Two Main Categories
GHRH Analogs
GHRH analogs are compounds related to growth hormone-releasing hormone. They act on the GHRH receptor and stimulate pituitary GH release through a pathway that resembles the body's natural hypothalamic signal.
This bucket includes sermorelin, CJC-1295, and tesamorelin. Sermorelin is a shorter GHRH(1-29) analog with a long history in endocrine practice. CJC-1295 is a longer-acting GHRH analog developed to extend exposure. Tesamorelin is a stabilized GHRH analog with FDA-approved use as EGRIFTA for reducing excess abdominal fat in HIV-infected adults with lipodystrophy (FDA EGRIFTA label).
Ghrelin Mimetics and GHS-R Agonists
Ghrelin mimetics act through the growth hormone secretagogue receptor, commonly called GHS-R1a. This is a different pathway from GHRH receptor activation.
Ipamorelin is commonly discussed as a selective GH secretagogue. Its foundational pharmacology paper described potent GH release in vitro and in animal models, with selectivity relative to older GHRPs, but this is not the same as large adult human outcome evidence (PubMed ipamorelin).
MK-677, also known as ibutamoren, is an oral ghrelin mimetic rather than an injectable peptide. In a randomized, double-blind, placebo-controlled study of 32 healthy older adults, MK-677 increased pulsatile GH release and raised IGF-1 into the young-adult normal range, but it also increased fasting glucose in the reported trial (PubMed MK-677).
What the Human Evidence Actually Shows
CJC-1295 has human pharmacokinetic and pharmacodynamic data. In two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, CJC-1295 produced dose-dependent increases in GH and IGF-1; after a single injection, mean plasma GH increased 2- to 10-fold for six days or more, and mean IGF-1 increased 1.5- to 3-fold for nine to eleven days (PubMed CJC-1295).
That is meaningful human endocrine signal data. It is not the same as proving long-term body composition, injury recovery, sleep, or longevity outcomes in a telehealth population.
Tesamorelin has stronger outcome data for a narrow indication. In a pooled analysis of two Phase 3 studies in 806 antiretroviral-treated HIV patients with excess abdominal fat, tesamorelin 2 mg daily reduced visceral adipose tissue by approximately -24 ± 41 cm² at week 26 versus +2 ± 35 cm² with placebo, with a treatment effect of -15.4% (PubMed tesamorelin).
The EGRIFTA label anchors the compliance boundary. EGRIFTA is indicated for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy, and the label states that long-term cardiovascular safety has not been established and that it is not indicated for weight-loss management (FDA EGRIFTA label).
MK-677 also shows human endocrine activity. In healthy older adults, 25 mg/day increased mean 24-hour GH concentration by 97% after two weeks and increased IGF-1 from 141 ± 21 micrograms/L at baseline to 265 ± 29 micrograms/L at four weeks, but fasting glucose also increased (PubMed MK-677).
Ipamorelin's most-cited selectivity story is more limited. The foundational paper characterized it as a potent selective GH secretagogue in vitro and in animal models, which supports mechanism and selectivity but does not establish large-scale adult clinical outcomes (PubMed ipamorelin).
Evidence-Graded Framing
The easiest mistake is to talk about "GH secretagogues" as if every compound has the same evidence base. They do not.
An evidence-graded hierarchy looks like this:
- FDA-approved, indication-specific outcome evidence: tesamorelin for excess abdominal fat in HIV-associated lipodystrophy.
- Human endocrine signal evidence: CJC-1295 and MK-677 show measurable GH/IGF-1 changes in human trials.
- Mechanistic and preclinical selectivity evidence: ipamorelin has strong pharmacology rationale but limited adult outcome trial data.
- Clinical extrapolation: body composition, recovery, sleep, and longevity claims often rely on mechanism, clinician experience, or indirect GH physiology rather than direct long-term RCTs.
That does not make the category uninteresting. It makes precision necessary.
Safety and Monitoring
The GH/IGF-1 axis is not a cosmetic pathway. It affects fluid balance, glucose metabolism, connective tissue, bone, growth signaling, and cellular proliferation. That is why screening matters.
Common clinical monitoring considerations include:
- IGF-1: to assess response and avoid chronically supraphysiologic signaling.
- Glucose metabolism: fasting glucose, HbA1c, insulin resistance risk, and diabetes history.
- Fluid and nerve symptoms: edema, joint discomfort, numbness, carpal tunnel-like symptoms, and headaches.
- Cancer history: active malignancy or significant cancer history requires careful clinician review because GH/IGF-1 signaling is growth-promoting.
- Pituitary history: especially relevant for tesamorelin, where the label includes contraindications related to hypothalamic-pituitary axis disruption (FDA EGRIFTA label).
The FDA's human growth hormone import alert is also relevant context. FDA states that approved HGH has limited approved uses, has serious known risks including possible increased cancer risk and reported nerve pain, elevated cholesterol, and elevated glucose, and is not approved for anti-aging, body mass, weight loss, libido, or stamina claims (FDA Import Alert 66-71).
GH secretagogues are not identical to HGH, but they point into the same endocrine axis. That makes casual, unscreened use a bad fit for a credible health brand.
Regulatory and Sport Caveats
Regulatory status varies by compound. Tesamorelin has an FDA-approved branded drug product for a specific indication. CJC-1295, ipamorelin, and many related peptides are not FDA-approved for general adult optimization. Sermorelin has a different historical and compounding profile than tesamorelin, but adult wellness claims still require careful legal review.
Compounding and telehealth workflows should not be built from internet assumptions. Pharmacy status, state availability, 503A and 503B rules, bulk substance status, approved-drug-copy restrictions, prescribing rationale, and marketing claims all matter.
Competitive athletes need a separate warning. WADA's 2026 Prohibited List includes GHRH and analogues such as CJC-1295, sermorelin, and tesamorelin, and also lists GHS mimetics including ibutamoren and ipamorelin under prohibited peptide hormones, growth factors, related substances, and mimetics (WADA 2026 Prohibited List).
Legal and regulatory decisions should be reviewed with a specialized healthcare attorney before acting on prescribing, sourcing, compounding, affiliate, telehealth, or marketing strategy.
How to Think About GH Secretagogues
The cleanest YourHealthRx framing is not "anti-aging peptides." It is endocrine signal literacy.
A serious GH secretagogue conversation should ask:
- Which receptor pathway is being targeted?
- Is the evidence human clinical outcome evidence, human endocrine signal evidence, or preclinical pharmacology?
- Is the patient an appropriate candidate?
- What is the baseline IGF-1 and metabolic profile?
- What safety history changes the risk-benefit analysis?
- Is the compound legally and ethically available through the proposed workflow?
- Is the patient a competitive athlete subject to anti-doping rules?
That framework makes the content more credible and more compliant.
Bottom Line
GH secretagogues are a real endocrine category, not a single product. They include GHRH analogs such as sermorelin, CJC-1295, and tesamorelin, and ghrelin/GHS-R agonists such as ipamorelin and MK-677.
The evidence is not uniform. Tesamorelin has the strongest indication-specific clinical evidence. CJC-1295 and MK-677 show measurable human GH/IGF-1 stimulation. Ipamorelin has compelling selectivity pharmacology but less adult outcome evidence.
For YourHealthRx, the responsible message is simple: signal matters, but monitoring matters more. A clinician-led GHS protocol should begin with endocrine context, safety screening, lab monitoring, and regulatory review, not a promise of recovery, longevity, or body transformation.
Informational only. This article is for informational and educational purposes only. It is not medical advice, does not create a patient-clinician relationship, and should not be used to diagnose, treat, cure, or prevent any disease. GH secretagogues, prescription medications, compounded medications, and off-label protocols should only be considered with a licensed clinician who can evaluate individual risks, contraindications, labs, medications, cancer history, metabolic status, and follow-up needs. Regulatory, pharmacy, telehealth, anti-doping, and compounding questions should be reviewed with a specialized healthcare attorney before business action is taken.
Sources: CJC-1295 (PubMed) · Tesamorelin Phase 3 (PubMed) · MK-677 (PubMed) · Ipamorelin (PubMed) · GHS Review (PMC) · FDA EGRIFTA label · FDA Import Alert 66-71 · WADA 2026 Prohibited List